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Abstract
Background: It is common practice, when using quantitative real time polymerase chain reaction (qPCR), to
normalise levels of mRNA to reference gene mRNA which, by definition, should not vary between tissue, with
any disease aetiology or after drug treatments. The complexity of human CNS means it unlikely that any
gene could fulfil these criteria.
Methods: To address this issue we measured levels of mRNA for six potential reference genes (GAPDH, PPIA,
SNCA, NOL9, TFB1M and SKP1) in three cortical regions (Brodmann’s areas (BA) 8, 9 and 44) from 30 subjects
with schizophrenia and 30 age and sex matched controls. We used a structured statistical approach to
examine the characteristics of these data to determine their suitability as reference genes. We also analysed
our data using reference genes selected by rank as defined using the average of the standard deviation of
pair-gene ΔCt and the BestKeeper, NormFinder and geNorm algorithms to determine if they suggested the
same reference genes.
Results: Our minimally derived data showed that levels of mRNA for all of the six genes varied between cortical regions
and therefore no gene fulfilled the absolute requirements for use as reference genes. As levels of some mRNA for some
genes did not vary with diagnoses within a cortical region from subjects with schizophrenia compared to
controls, we normalised levels of mRNA for all the other genes to mRNA for one, two or three reference
genes in each cortical region. This showed that using the geometric mean of at least two reference genes
gave more reproducible results. Finally, using the reference gene ranking protocols the average of the standard deviation
of pair-gene ΔCt, BestKeeper, NormFinder and geNorm we showed that these approaches ranked potential reference
genes differently. We then showed that outcomes of comparing data from subjects with schizophrenia and controls
varied depending on the reference genes chosen.
Conclusions: Our data shows that the selection of reference genes is a significant component of qPCR study design and
therefore the process by which reference genes are selected must be clearly listed as a potential confound in studying
gene expression in human CNS. This should include showing that, using minimally derived qPCR data, levels of mRNA
for proposed reference genes does not vary with variables such as diagnoses and CNS region.
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Background
Quantitative real time polymerase chain reaction (qPCR)
is widely used to measure levels of mRNA in biological
samples. As qPCR aims to quantify mRNA in tissue, var-
iables such as the efficiencies of extracting RNA and dif-
ferences in the synthesis of cDNA from RNA in
different samples could be significant experimental con-
founds. It is now a wide spread practice to normalise
data to levels of mRNA from a gene designated as a ref-
erence gene [1]; a reference, or housekeeping, gene being
a gene that gives levels of mRNA that do not vary be-
tween different biological samples, are not affected by
any experimental procedure or disease aetiologies [2].
Such stable expression properties should mean that nor-
malising levels of less stable genes to the reference gene
controls for confounds such as tissue mRNA extraction
and variability in cDNA synthesis across different sam-
ples. However, it has long been recognised that finding
genes that meet the precepts of a reference gene is a sig-
nificant challenge [3].
The complexity of the central nervous system (CNS)
means it is a particularly difficult organ in which to find
genes with expression characteristics consistent with
that of a reference gene. Indeed, current data suggests
that finding genes with expression levels that do not vary
between CNS region and disease state may not be feas-
ible [4–6]. Similarly, there is a question as to whether
there are genes that can be designated reference genes
in studies comparing gene expression in CNS and per-
ipheral tissue [7]. To tackle these problems attempts
have been made to develop algorithms that can rank
genes in order of suitability for use as a reference gene
using data from qPCR [5]. Unfortunately, given the same
data sets, different algorithms will suggest different ref-
erence genes and thus study outcomes can vary depend-
ing on the algorithms used to select reference genes [1].
It is now widely accepted that psychiatric disorders
such as schizophrenia occur in individuals with a genetic
predisposition after they have encountered environmen-
tal triggers that lead to the frank onset of illness [8]. The
impact of the interaction between genes and environ-
ment occurs through epigenetic mechanisms that bring
about changes in CNS gene expression [9] and therefore
measuring gene expression in the CNS of subjects with
psychiatric disorders has been used to gain insight into
their aetiologies [10]. However, it is now increasingly
recognised that the study of gene expression in CNS
from subjects with psychiatric disorders such as schizo-
phrenia is hampered by problems in identifying suitable
reference genes for data normalisation [11, 12]. It has
been suggested that problems with variability in refer-
ence genes in post-mortem CNS from subjects with psy-
chiatric disorders can be overcome by using the
geometric mean of levels of three reference genes [13].
However, this solution is still dependent on being able to
identify reference genes with appropriate expression
characteristics.
We have addressed the issue of identifying reference
genes by examining levels of mRNA for three commonly
used reference genes (glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), peptidylprolyl isomerase A (cyclophilin
A) (PPIA), synuclein, alpha (non A4 component of amyloid
precursor) (SNCA) in three human cortical regions. We
also measured mRNA levels of three genes, nucleolar pro-
tein 9 (NOL9), transcription factor B1, mitochondrial
(TFB1M) and S-phase kinase-associated protein 1 (SKP1)),
that we had identified as potential reference genes from
publically available microarray data from human CNS using
the Genevestigator platform [14].
Whilst practical issues support expressing data from
qPCR as a ratio of one or more reference genes, the
transformation of data into ratios introduces inherent
problems in subsequent statistical analyses [15–17]. This
is because i) there may not be a linear relationship be-
tween the numerator and denominator, ii) if there is not
a zero intercept between the numerator and denomin-
ator this will make the measure of the denominator a
confounding effect, iii) minor departures from a zero
intercept can have major consequences on the ratio’s
ability to control for the denominator, iv) the use of ra-
tios cannot easily take nonlinear effects between the nu-
merator and denominator into account, v) the use of
ratios can introduce spurious correlations among the ra-
tios and other variables, vi) the use of ratios can create
interpretive difficulties and importantly vi) the use of ra-
tios affects the error distribution of the data which may
also violate the assumptions of subsequent parametric
statistical analyses. Hence, to attempt to avoid analysing
data in the form of ratio to identify potential reference
genes we used a relatively underived data to identify char-
acteristics in gene expression that best fit with a gene suit-
able for use as a reference gene. We then compared genes
we identified as potential reference genes to outcomes
suggested by other approaches using our data from sub-
jects with schizophrenia with respect to controls. The
other approaches to identifying reference genes included
using the average of the standard deviation of pair-gene
ΔCt [18] and three published algorithms (BestKeeper [19],
NormFinder [20] and geNorm [21]) that have been devel-




Approval to collect tissue used in these studies was ob-
tained from the Ethics Committee of the Victorian Institute
of Forensic Medicine and the Mental Health Research In-
stitute. Tissue was collected following consent been gained
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from the next-of-kin and supplied by the Victorian Brain
Bank Network.
For these studies, tissue was collected from Brodmann’s
area (BA) 8 (defined as being primarily in the superior
frontal gyrus and extending from the cingulate sulcus on
the medial surface to the middle frontal gyrus), 9 (the lat-
eral surface of the frontal lobe including the middle frontal
gyrus superior to the inferior frontal sulcus) and 44 (the
region occupying the opercular region of the inferior
frontal gyrus, bounded rostrally by the ascending limb of
the lateral sulcus and caudally by the inferior precentral
sulcus) from the left hemisphere from 30 subjects who
had suffered from schizophrenia and 30 age and sex
matched subjects with no history of psychiatric illness
(controls). A case history review was completed using the
Diagnostic Instrument for Brain Studies [22, 23]. During
the case history review suicide completion was recorded
when listed in the Coroner’s report. Duration of illness
(DI) was calculated as time from first clinical presentation
to a psychiatric service to death. The final recorded dose
of antipsychotic drug (FRADD) was recorded and con-
verted to chlorpromazine equivalents using algorithms as
proposed in the literature [24], as was total lifetime expos-
ure to such drugs (LEAP). On completion of the case his-
tory review diagnoses were made according to DSM-IV
criteria by consensus between a psychologist and a senior
psychiatrist.
All cadavers were refrigerated within 5 h of being
found. When death was witnessed, post-mortem interval
(PMI) was calculated as the time from death to autopsy.
Where death was not witnessed, tissue was only col-
lected from subjects who had been seen alive up to 5 h
prior to being found dead; here the PMI was taken as
the midpoint between the person being found and being
last seen alive. As well as maintaining cases at low tem-
peratures for most of their PMI, tissue was rapidly proc-
essed and frozen to -70 °C within 30 min of autopsy
[25]; processing tissue in this way significantly slows
autolytic changes [26]. CNS pH was measured as de-
scribed previously [27] as this provides a good measure
of overall tissue quality [28].
RNA purification and first-strand cDNA synthesis
Total RNA was isolated from 100 mg frozen tissue using
1 mLTRIzol ® reagent (ThermoFisher Scientific, Waltham,
MA USA) according to the manufacturer’s instructions.
The RNA was treated with DNase I (ThermoFisher Scien-
tific) at 37 ° C for 25 – 30 min and then purified by phe-
nol/chloroform extraction and stored at -80 ° C. RNA
quantity and quality were determined by spectrophotom-
eter readings (NanoDrop, ThermoFisher Scientific) and
RNA integrity numbers (RINs) obtained from an Agilent
2100 bioanalyser [29]. Genomic DNA elimination was
confirmed by PCR using primers specific for genomic
DNA. First strand cDNA was synthesized from 2 μg RNA
using 100 units M-MLV-RT (ThermoFisher Scientific)
with 2.5 μM random decamers and 2.5 μM oligo dT
primers (ThermoFisher Scientific), 0.5 mM of each dNTP
and 20 units RNase inhibitor in RT Buffer (50 mM Tris–
HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 and 5 mM DTT)
in a final volume of 20 μL. The reaction was incubated at
44 ° C for 1 h then inactivated at 92 ° C and the product
aliquoted and stored at -20 ° C.
Real-time PCR assay
We chose 6 potential reference genes using 2 criteria.
Levels of GAPDH, PPIA and SNCA were measured be-
cause they have been used widely as reference genes in
the studies using human CNS [21, 30]; levels of NOL9,
TFB1M and SKP1 were measured because we had used
these genes as reference genes in a previous study [31]
having first selected them as potential reference genes
from microarray data [32].
cDNA was used as a template for real-time PCR. Reac-
tions were performed, in triplicate, in a Bio-Rad iQ5 Real-
Time PCR Detection System with Bio-Rad iQ5 optical sys-
tem 2.0 software (Bio-Rad, Hercules, CA) in 50 μL volume
containing cDNA diluted 1:125, 0.4 nM primers and 1 x
IQ SYBR green supermix (Bio-Rad), with cycling condi-
tions of 95 ° C for 3 min, 40 cycles of 30 s each at 95 ° C,
57 ° C and 72 ° C, followed by a melt curve. Relative quan-
tity was determined corrected for reaction efficiencies
using the Pfaffl method [33]. Primers (Additional file 1:
Table S1) were deemed acceptable if they gave reaction effi-
ciencies, calculated from standard curves run on each plate
constructed from a 10-fold dilution series of the human
CNS cDNA, of between 90 and 110 % and were shown to
amplify the expected gene according to the nucleotide se-
quence of their amplicon. The standard curves run for
every gene on every plate were made from the same batch
of cDNA and any minor plate to plate variation was cor-
rected to a calibrator sample, prepared from a subject that
was not part of the cohort, which was included on every
plate. Analyses of melt curves showed there was no non-
specific amplification or primer dimerization (Additional
file 2: Figure S1).
Statistics
Cohort age, PMI and CNS pH were compared between
diagnoses using the Student’s t-test. Gender frequency
was compared using a χ2 test. Relationships between
age, PMI, DI, CNS pH, RIN, FRADD and LEAP and ex-
perimental data were determined using linear regression
and the resulting coefficient of determination. The small
sample sizes in this study meant that only strong rela-
tionships, r2 ≥ 0.49 [34], warranted further consideration
as potential confound. Where there were strong
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correlations non-experimental data were included as co-
variates when analysing experimental data.
For “in house” analyses using raw and derived data
we made minimal assumptions about the nature of
the data. However, the qPCR data sets showed a com-
plex mixture of parametric and non-parametric distri-
bution and hence we used non-parametric analyses
(Mann–Whitney U test or Kruskal-Wallis test) as
these types of analyses best identify differences be-
tween such mixed data [35].
Another approach to identifying potential reference
genes was to calculate the ΔCTs for each combination of
potential reference gene pair in a single tissue sample,
and compare the standard deviations of ΔCT for each
gene pair across the sample set [18]. To assess the simi-
larities to our approach of prioritizing genes according
to a lack of variation between diagnoses we analysed our
data as suggested when using the ΔCT method.
We also analysed our data using three algorithms
(BestKeeper [19], NormFinder [20] and geNorm [21])
designed to rank genes in order of their stability of
expression and hence suitability for use as reference
genes. These algorithms used different approaches to
attempt to identify genes that have expression profiles
best suited to them being used as reference genes.
Hence, BestKeeper uses repeated pair-wise correlation
to identify highly correlated genes, and takes into ac-
count the calculated variations of each gene across
samples, to choose the best reference genes. The geo-
metric mean of the best reference genes is then cal-
culated to form an index, against which each
reference gene can be correlated to describe the rela-
tion between the index and the contributing candi-
date reference gene. NormFinder selects for suitable
candidate genes based on minimal variation estimates
across all samples, rather than selecting genes with
the highest degree of similarity of expression profile
across the sample set. This eliminates the possible ef-
fects of there being co-regulated genes among the
candidates and reduces the risk of rejecting an opti-
mal candidate based on a different pattern of expres-
sion across the sample set compared to the other
genes being tested. An additional optional step in the
analysis allows for identifying the number of genes to
include based on the intragroup variance, which was
not performed in the current study. Finally, geNorm
assesses the variation in expression between two can-
didate reference genes based on the standard devi-
ation of log-transformed gene ratios. The gene-
stability measure M is calculated using the average
pairwise variation of a gene against all other candi-
date genes measured. Stepwise exclusion of the gene
with the highest M value results in decrease of the M
value until the three most stable genes remain.
For this study we accessed these 3 algorithms using
RefFinder [36] which integrates these algorithms and
compares the rankings across algorithms; data were en-
tered as mean raw Ct values within each cortical region
and all samples and genes were analysed simultaneously.
Results
Human CNS collection
There were no significant differences in gender ratio, age,
PMI or RINs between subjects with schizophrenia and the
controls (Additional file 3: Table S2). There was a small
but significant difference in CNS pH with diagnoses, the
CNS pH being lower in the tissue from subjects with
schizophrenia (mean pH = 6.26) versus controls (mean
pH = 6.36; p = 0.03).
Real-time PCR
Regression analyses of data from the standard curves for
GAPDH, PPIA, SNCA, NOL9, TFB1M and SKP1 showed
the y intercept when x = 0 were -0.004, -0.012, -0.013, -
0.008, -0.018 and 0.0000002, respectively. Thus, whilst
these are minor variations they could have major conse-
quences for controlling for the denominator in ongoing
analyses of our data and further support the use of non-
parametric tests in these analyses.
Using raw data corrected for efficiency of amplification
(relative quantities), levels of mRNA for every gene varied
between cortical regions in either the control subjects or
the subjects with schizophrenia (Fig. 1). Focusing on vari-
ation with diagnoses within each cortical region, there
were significantly lower levels of PPIA, SNCA and NOL9
mRNA as well as a strong trend towards significantly
lower levels of GAPDH in BA 8 and a trend to lower levels
of SKP1 in BA 9 from subjects with schizophrenia com-
pared to control (Fig. 2).
There are a number of confounds that could be affecting
gene expression but our data showed that relationships be-
tween levels of GAPDH, PPIA, SNCA, NOL9 and TFB1M
mRNA did not show significant deviation from a slope of
0 when correlated with age, PMI, CNS pH and DI in BA 8
(Additional file 4: Table S3). The correlations between RIN
and levels of PPIA and TFB1M as well as SKP1 and pH de-
viated significantly from 0 but the coefficient of determin-
ation showed these relationships to be extremely weak
(0.110 to 0.114) (Additional file 5: Figure S2). In BA 9, the
correlations between RIN and levels of GAPDH, SNCA,
NOL9 and TFB1M deviated significantly from 0 but the
coefficient of determination showed these relationships to
be extremely weak (r2 from 0.07 to 0.17; Additional file 4:
Table S3 and Additional file 5: Figure S2). In BA 44, the
correlations between CNS pH and GAPDH, SNCA and
NOL9 as well as RIN for mRNA levels for all genes devi-
ated significantly from 0 but the coefficient of deter-
mination showed these relationships to be extremely
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weak (r2 from 0.078 to 0.163; Additional file 4: Table S3
and Additional file 6: Figure S3). Thus, we concluded
that the commonly examined confounds associated
with postmortem research in psychiatric disorders were
not contributing significantly to the levels of the cor-
tical mRNA measured in this study.
To begin assessing the value of using one or more refer-
ence genes to normalise data from postmortem CNS we
noted that levels of mRNA for SKP1 and TFB1M did not
vary significantly with diagnoses in any of the cortical re-
gions studied. Thus, we normalise levels of genes other
than the selected reference gene to levels of either SKP1
or TFB1M mRNA. These analyses showed that levels of
mRNA of GAPDH, PPIA, SNCA, NOL9 and TFB1M nor-
malised to SKP1 mRNA did not differ in BA 8, 9 and 44
from subjects with schizophrenia compared to controls
(Fig. 3a-c). By contrast, when levels of mRNA were nor-
malised to TFB1M levels of GAPDH (p = 0.04) and SNCA
(p = 0.04) mRNA were significantly higher in BA 8
(Fig. 3d), there was a very strong trend to higher relative
expression of GAPDH (p = 0.05) in BA 9 (Fig. 3e) and the
relative expression of SNCA (p = 0.03) and NOL9 (p =
0.04) were lower in BA 44 (Fig. 3f) in schizophrenia.
These data showed the use of a single reference gene runs
the risk of introducing a bias and therefore strengthens
the argument to use the geometric mean of multiple refer-
ence genes.
Next we used the geometric mean of TFB1M and SKP1
to normalise levels of mRNA for the other genes in BA 8, 9
and 44 (Fig. 4a-c). These analyses showed there were no sig-
nificant differences in levels of mRNA for GAPDH, PPIA,
SNCA and NOL9 in BA 8 (Fig. 4a). In BA 9 there were
Fig. 1 Levels (Median ± Range) of GAPDH, PPIA, SNCA, NOL9, TFB1M and SKP1 mRNA in BA 8, 9 and 44 from control subjects and subjects who
had schizophrenia
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Fig. 2 Levels (Median ± Range) of GAPDH, PPIA, SNCA, NOL9, TFB1M and SKP1 mRNA in BA 8, 9 and 44 from control subjects and subjects who
have had schizophrenia
Fig. 3 Levels (Median ± Range) of GAPDH, PPIA, SNCA, NOL9 and TFB1M mRNA normalised to SKP1 mRNA (a-c) and GAPDH, PPIA, SNCA, NOL9 and
SKP1 mRNA normalised to TFB1M mRNA (d-f) in BA 8, 9 and 44 from control subjects and subjects who had schizophrenia
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higher levels of GAPDH (p= 0.03) and SNCA (p= 0.04) in
the cortex of subjects with schizophrenia (Fig. 4b);
there was also a trend (p = 0.08) toward higher levels
of PPIA mRNA. In BA 44 there were lower levels of
SNCA (p = 0.03) and NOL9 (p = 0.03), and a strong
trend to lower levels of PPIA (p = 0.06), mRNA in
subjects with schizophrenia (Fig. 4c).
We then used the mean of three reference genes to
normalise data, acknowledging that levels of mRNA for
all the other genes changed with diagnosis in at least
one of the three cortical regions. To overcome this
limitation we used the geometric mean of SKP1,
TFB1M and NOL9 in BA 8 and 9 and the geometric
mean of SKP1, TFB1M and GAPDH in BA 44. These
analyses showed i) a strong trend to higher levels of
GAPDH mRNA (p = 0.06) in BA 8 (Fig. 4d), ii) higher
levels of GAPDH (p = 0.02) and SNCA (p = 0.04) mRNA
in BA 9 (Fig. 4e) and iii) lower levels of PPIA (p = 0.04),
SNCA (p = 0.02) and NOL9 (p = 0.04) in BA 44 (Fig. 4f )
from subjects with schizophrenia.
RNA Integrity Number (RIN) as a potential confound in
reference gene identification
It has been suggested that qPCR should not be used to
measure mRNA in postmortem CNS with RINs < 5 [37]. It
was notable in this study that there were no strong correla-
tions between RIN and levels of mRNA in any of the cor-
tical regions studied (Additional file 4: Table S3 and
Fig. 4 Levels (Median ± Range) of GAPDH, PPIA, SNCA, NOL9 mRNA normalised to the geometric mean of SKP1 and TFB1M mRNA (a-c), GAPDH,
PPIA, SNCA normalised to the geometric mean of SKP1, TFB1M and NOL9 (d and e) or PPIA, SNCA and NOL9 normalised to the geometric mean of
SKP1, TFB1M and GAPDH (f) mRNA in cortical tissue from control subjects and subjects who have had schizophrenia. Levels (Median ± Range) of
GAPDH, PPIA and SNCA normalised to SKP1, TFB1M and NOL9 (g) or PPIA, SNCA and NOL9 normalised to the geometric mean of SKP1, TFB1M and
GAPDH (h) where only data on mRNA from cases with RIN > 5 is also shown
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Additional file 6: Figure S3). This suggested that levels of
mRNA for the genes of interest in our study were relatively
stable compared to the overall measure of mRNA stability
provided by RINs. To test this hypothesis we compared
levels of mRNA for our genes of interest in BA 8 and BA
44 which had RINs < 5.0 to the data from all cases and
showed levels of mRNA did not vary significantly between
the two groups (BA 8: GAPDH p = 0.66, PPIA p = 0.89 and
SNCA p = 0.41 and BA 44: GAPDH p = 0.98, PPIA p = 0.95
and SNCA p = 0.96). We then compared levels of mRNA
across diagnoses in BA 8 and BA 44 excluding data from
cases with RIN < 5; analyses which showed the loss of
the strong trend to higher levels of GAPDH in BA 8
from subjects with schizophrenia (Fig. 4g) that was
present using data from the whole cohort (Fig. 4d).
By contrast, the lower levels of mRNA for PPIA,
SNCA and NOL9 that were apparent in BA 44 when
all the data was included in the analyses (Fig. 4f )
were still significantly lower (PPIA (p = 0.04), SNCA
(p = 0.02) and NOL 9 (p = 0.03) when only case with a
RIN > 5.0 were included (Fig. 4h).
Comparison of different reference gene identification
methodologies
When our ΔCT ratios underwent parametric analyses, as is
suggested when using this model, the best performing genes
(ranked according to the mean of the standard deviations
for each gene pair ratio) in BA 8 were SNCA,
TFB1M and PPIA, in 9 were SNCA, PPIA and
TFB1M and in BA 44 were PPIA, GAPDH and SNCA
(Additional file 7: Table S4). We then compared data
from the 3 genes not used as reference genes and
expressed as the geometric mean of SNCA, TFB1M
and PPIA in BA 8, SNCA, PPIA and TFB1M in BA 9
and PPIA, GAPDH and SNCA in BA 44 from sub-
jects with schizophrenia and controls. There were no
significant changes in mRNA levels between diagno-
ses in BA 8 (Fig. 5a) or 44 (Fig. 5c); there was a
strong trend to higher levels of GAPDH mRNA in
BA 9 from subjects with schizophrenia (Fig. 5b).
A number of algorithms have been developed that can
be used to rank genes in order of stability for use as ref-
erence genes. In BA 8, no algorithms rank the same
three genes as the best candidates to use as reference
genes (Additional file 8: Table S5). Using the suggested 3
genes from BestKeeper showed a trend to higher levels
of TFB1M in BA 8 from subjects with schizophrenia
(Fig. 5d), NormFinder did not reveal any significant vari-
ation with diagnoses in that cortical region (Fig. 5g)
whilst using reference genes suggested by geNorm
showed a strong trend to lower levels of NOL9 in sub-
jects with schizophrenia (Fig. 5j). BestKeeper suggested
the same 3 genes (GAPDH, TFB1M and PPIA) should be
used as reference genes in BA 9 and 44; using these
reference genes meant there was no significant variation
in levels of mRNA with diagnoses in BA 9 (Fig. 5e) but
there were trends to lower levels of SNCA and NOL9 in
BA 44 for people with schizophrenia (Fig. 5f ). NormFin-
der and geNorm gave the same sets of three genes as the
best to use as reference genes in BA 9 (SNCA, PPIA and
TFB1M) and BA 44 (PPIA, GAPDH and SNCA). Using
the appropriate sets of reference genes showed there
were no significant variations in levels of mRNA with
diagnoses in BA 9 of BA 44 (Fig. 5h and i) in schizo-
phrenia compared to controls.
Discussion
Identifying reference genes that truly fulfil the required
criteria for such genes [3] has been shown to be difficult.
Hence, we took our data quantifying mRNA in three cor-
tical regions from subjects with schizophrenia and con-
trols and subjected them to analyses using a structured “in
house” statistically driven approach that initially involved
using minimally derived data and compared the three
genes that appeared to have the best properties associated
with reference genes to those recommended by four other
approaches to identifying reference genes using qPCR
data. Of the 6 genes we measured that could have poten-
tially fulfilled the criteria to be reference genes, we found
that levels of mRNA for all of the genes varied across cor-
tical regions; these data add to that of others [4–6] to
argue that finding genes with stable expression across
many CNS regions will be extremely difficult. One study
has reported levels of mRNA for G protein pathway sup-
pressor 1 (GPS1) and ubiquitin conjugating enzyme E2D
2 (UBE2D2) and suggested these genes could be used as
CNS wide reference genes [38]. However, that study was
carried out using tissue from two donors and therefore
lacked significant power to discover inter-person variabil-
ity in gene expression across the CNS but the study pro-
vides preliminary data to support the notion that some
genes might be able to be used as reference genes across
CNS regions. Thus, until these data are replicated in larger
collections of CNS it would seem that comparisons of
gene expression in post-mortem CNS across diagnoses
may need to be carried out within a CNS region without
comparing results across multiple CNS regions.
As we could not use a single set of reference genes
across multiple cortical regions to normalise qPCR data
we then determined if any of our six genes could be
used as reference genes within a cortical region. Using
our statistically driven approach we identified up to
three of the six genes which fulfilled the criteria for refer-
ence genes within each cortical region, that is levels of
mRNA did not vary with diagnoses in that region. Then,
within each cortical region, we confirmed that using mul-
tiple reference genes gave more stable outcomes although
we did not observe any great differences in outcomes
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using two, compared to the recommended three [13], ref-
erence genes. Our data also suggested that if levels of
mRNA are not correlated to RIN then data from tissue
where cases had RINs < 5.0 did not affect comparisons of
data across diagnoses. Finally, we showed that the use of
four different approaches to identifying reference genes
did not suggest the same genes which obviously affected
subsequent comparisons across diagnoses within each of
the three cortical regions. Thus, our study emphasises that
the selection of reference genes is critical for studies
examining gene expression using postmortem CNS from
subjects with psychiatric disorders such as schizophrenia,
and this must be acknowledged as a confound when com-
paring results from different studies.
Turning to our data across diagnoses, our analyses using
the geometric mean of levels of mRNA of three region spe-
cific reference genes identified using our internal approach
showed that levels of GAPDH and SNCA mRNA were
higher in BA 9 from subjects with schizophrenia compared
to controls. By contrast, in BA 44 levels of PPIA, SNCA and
NOL9 were lower in subjects with schizophrenia. Our data
are partly supported by another study that reported higher
levels of GAPDH mRNA in the cortex of subjects with
schizophrenia [39]. Notably, GAPDH protein has been re-
ported as decreased in the cortex from subjects with
schizophrenia [40], suggesting the increase in gene expres-
sion may be an attempt to compensate for low protein
levels. As in our study, lower levels of PPIA mRNA have
been reported in the cortex of subjects with schizophrenia
[41]. By contrast we are aware of no studies reporting
change in levels of SNCA or NOL9 mRNA in the cortex
of subjects with schizophrenia. However, the presence of
higher levels of SNCA protein in the layer 2 of the insular
cortex suggests changes in SNCA gene expression are
present in the CNS of subjects with schizophrenia [42].
GAPDH encodes a protein that has roles in glycolysis
and the control of nuclear function and so it can influ-
ence many aspects of cellular development [43], SNCA
Fig. 5 Levels (Median ± Range) of genes of interest in BA 8, 9 and BA 44 normalised to the geometric mean of reference genes identified using
ΔCT Ratios (a-c), BestKeeper (d-f), NormFinder (g-i) or geNorm (j,h,i) ranking
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encodes a protein that is a pre-synaptic protein involved
in neurotransmitter release [44], PPIA encodes a protein
that is an intracellular protein that regulates protein
folding and trafficking [45] whilst NOL9 encodes a pro-
tein that is a novel polynucleotide 5′-kinase involved in
ribosomal RNA processing [46]. Hence changes in the
expression of any of these four genes could have pro-
found effects on cortical function and therefore deserve
further investigation, but such investigations were be-
yond the scope of our current studies.
Analysing our data on mRNA levels for six genes from
60 individuals in three cortical regions from subjects with
schizophrenia shows the choice of reference genes can have
a significant impact on the outcomes from subsequent stat-
istical analyses. Moreover, whilst the notion of expressing
results as a ratio to a reference gene to attempt to control
for methodological variables such as RNA extraction and
cDNA synthesis has clear merit, the subsequent need for
statistical analyses using ratios is a clear confound. There is
a growing focus on making sure researchers impose high
levels of quality control on their methodologies [47]; this is
particularly important when completing a quantitative
methodology. Whilst the conflict between the need for the
use of reference genes and the subsequent problems in data
analyses seems unresolvable there are some ways to minim-
ise the impact of potential ambiguity in analysing data in
the form of ratios. First, linear regression analyses of the
standard curve for each gene should be completed and the
y-axis intercept determined. If the y-axis intercept for these
lines is not zero and does vary between gene then the sub-
sequent data analyses should use non-parametric ap-
proaches [15]. The analysis of our data would argue that,
when comparing levels of mRNA in the same CNS region
from subjects with different psychiatric disorders, using
minimally derived data as a starting point to identifying po-
tential reference genes is worthwhile as it can show differ-
ences of level of absolute gene expression with diagnoses.
We would argue that, whether or not these differences are
real or are reflective of some bias in RNA processing, the
use of such genes as reference genes should be avoided.
The suggestion that all data on genes of interest should be
expressed as the geometric mean of three reference gene to
stabilise outcomes from subsequent statistical analyses [13]
has clear merit. However it could be worthwhile to present
analyses of qPCR data at the level of underived data and as
a geometric mean as one method may show differences be-
cause of sample processing bias and the other of statistical
processing but, more importantly, if both analyses show the
same outcome then this would suggest any differences are
due to disease process and not sample or data processing.
Conclusions
Our attempts to identify suitable reference genes to in-
vestigate changes in gene expression in multiple regions
of the cortex from subjects with schizophrenia and con-
trols has added to the notion that reference genes, ac-
cording to the definitive criteria, do not exist in the
human CNS. Our data suggests comparing levels of
gene expression normalised to multiple reference genes
are possible within defined cytoarchitectural regions
which may mean it could be necessary to identify spe-
cific reference genes for discrete nuclei such as those in
the hippocampus and amygdala. Our data argues that
all studies reporting qPCR data using normalised gene
expression need to show, using minimally derived data,
that levels of mRNA for the reference genes do not vary
with diagnoses or conditions, as set out in the MIQE
guidelines [48], rather than simply stating the genes
used were picked using ranking algorithms. In addition,
as we and others [11], have shown, the use of algorithms
to identify reference genes is a confound within any
study that should be acknowledged. We have also rec-
ommended other analyses that should be completed
and reported to give added comfort that an effort has
been made to address the conflict between the need
to express qPCR data as a ratio of reference genes
and subsequent analyses of such derived data. Finally,
as has been suggested previously [49], the problem in
finding reference genes in the human CNS should be
noted when measuring proteins using Western blots
where supposed reference proteins (loading controls),
are used to normalise data even though some proteins
used as loading controls, such as GAPDH, have been
shown to vary in levels in the CNS of subjects with
psychiatric disorders.
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